TMCnet News
Applied Therapeutics to Present Data on AT-001 for Treatment of Diabetic Cardiomyopathy at 56th Annual Meeting of the European Association for the Study of DiabetesNEW YORK, Sept. 17, 2020 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, announced today that it will present two poster presentations covering AT-001, a next generation aldose reductase inhibitor (ARI), in Phase 3 development for Diabetic Cardiomyopathy at the upcoming 56th Annual Meeting of the European Association for the Study of Diabetes (EASD). The presentations include data on the safety and specificity of AT-001, as well as data on mechanistic protection from cellular damage during hyperglycemia. “We are pleased to present data at EASD supporting development of AT-001 for diabetic complications,” said Riccardo Perfetti, MD, PhD, Chief Medical Officer of Applied Therapeutics. “We have previously presented data on the improved potency and clinical safety profile of AT-001, which is currently in a global registrational study for Diabetic Cardiomyopathy. The data presented at EASD demonstrates the improved target selectivity vs. “old” ARIs, underscoring AT-001’s improved clinical safety profile, as well as compelling mechanistic data demonstrating AT-001 protection from damage caused by hyperglycemia.” Presentation Details Poster #629: AT-001 a new aldose reductase inhibitor wth improved selectivity and specificity protects from cellular damage Time: Wednesday, September 23, 12:00 – 1:00 p.m. CEST (6:00 – 7:00 a.m. EDT) Poster # 632: Addressing safety and specificity with aldose reductase inhibition: development of AT-001 for diabetic cardiomyopathy Slides will be available on the presentations and publications section of the Applied Therapeutics website following the conference. About Applied Therapeutics About AT-001 Investors: Media: |